Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Are there other chances left which aren't external to Mast?
Mast alone means to go bankrupt by 2018.
Since 2013 Mast needed a partnership for Vepo, but this was impossible due to the poor clarity of effectiveness.
Now Mast has 2 P2 close to the end and another bigger started in August with NIH.These tests are sponsored and few expensive for the Co. early results look good and innovative even as market potential.
The Ceo should plan a partnership to start a P3 in 2017. Something similar to that Aires did with Novartis: some cash to start,then on milestones or on interim and sales-rights or right to buy. Aires Therapeutics that developed AIR001, before the business reorganization of Novartis, entered into a contract with this big Pharma for $20M in a P2 for PAH(Pulmonary Arterial Hypertension) and up to $250M of rights of sale.
AIR001 is tested by mast both in PAH and in HFpEF,then market even bigger. Let us hope the CEO ability for once is equal to the task.
I hope BC has begun the conversations to partner AIR already weeks or better months ago,surely there are big chances for this drug if in the right hands.
This month the prestigious medical journal Circulation Research published 2 articles about an interim results of the AIR001 P2, very positive and exciting.
Above all they fund Sodium nitrite effective in HF and PAH, where other NOs (Nitric Oxide) donors drugs,like Sidenafil, failed.
They also proof for the first time that Inhaled Nitrite works well as injected Nitrite with catheters.This is huge for patients and obviously also for the marketing.
It shouldn't difficult find a good partnership or even a merger or BO, the last opportunity for Mast,enough big to recover the disaster.IMO
useless
very informative RhodeyRed123 on StockTwits: 25 points from 36 minuntes conversation with Culley about EPIC delay and other outlook.
Everyone should read it on StockTwits. Very interesting for longs
okaly u r one of the lunatics on this board. RhodeyRed123 talked with Culley yesterday and shared it on StockTwits. Very kind person and well-informed. He shared great info heard directly from Culley about EPIC and delay.
I suggest all people to read it on StockTwits: very useful.
Why so negative when Culley finally speak clearly and detailed? Is 1 month of delay so bad?
No. It means instead that the amount of data is really impressive, EPIC is a milestone in the SCD research. They are removing the incongruities and the omissions in the clinic data asking the hospitals and the doctors.
It seems they want data perfectly cleaned and complete above all to avoid approximations and to measure accurately all secondary endpoints, specially the recurring VOCs and the ACS during the 30 days of follow up. A very important point that can expand the use of Vepo in the therapy of SCD and its commercialisation.
It is worth it.
they are talking about commercialisation at the national conference of Association of Bioscience Financial Officers (ABFO)
Brandi Roberts speeches
Yesterday 2:00 pm
MODERATOR - Brandi Roberts, Chief Financial Officer, Mast Therapeutics, Inc.
This moderated roundtable discussion will focus on issues commonly faced by mature life science companies that have been public for three years or more and have or are about to launch commercial products. Topics will include product launch challenges, considerations and best practices, international expansion issues, distribution models, FCPA, tax planning strategies and ERP-related issues, amongst others.
Today 10:15 am and 12:50 am
C. "Best Practices for Managing Global Clinical Finance"
Are your corporate finance interests and clinical trial goals aligned? This panel of experts from Ernst & Young, Mast Therapeutics, Mirati Therapeutics, and Medidata Solutions will discuss best practices for managing global clinical finance across your R&D portfolio. They’ll address common pitfalls when it comes to managing the site payment process on global trials, managing accruals, forecasting and transparency reporting, outsourcing clinical finance operations, and selecting technology.
here the Agenda
http://www.abfointernational.org/2016/2016Agenda.html
..
Usually they use Wilcoxon rank test to calculate p-value, having all the rows of data, using only the mean and the SD the t-test should be a valid option,I think.
I used this online calculator. If somebody wants play with numbers.
http://graphpad.com/quickcalcs/ttest1/?Format=SD
Boo,the interim at 250,if confirmed, could give a HUGE result,with a stellar P-value .
I did also Yesterday some simulations with those data of the P-Value and t-value
if the placebo arm is confirmed around 96 hrs (a supposed value) the results will have very, very high statistical significate.
We'll see soon how correct were these interim data.
If you select the correct time in the box you can see the range you want.
But nobody uses the chart of a company site, always few complete and few user friendly
http://masttherapeutics.com/investors/stock-information/?pg=stockchart&time=10yr&freq=1dy
2 new AIR001 trials.
Already mentioned NCT02694393
"Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis"
start Feb 2016
end 2017
and
NCT02713126
12 Week Study of Inhaled Nitrite for Improving Cardiac Function
start April 2016
end 2020
source: CinicalTrials.gov
here the links
https://clinicaltrials.gov/ct2/show/NCT02694393?term=mast+therapeutics&rank=15
https://clinicaltrials.gov/ct2/show/NCT02713126?term=mast+therapeutics&rank=16
Pray,are you kidding me?
I reported a new trial started in February 2016 presents on the database ClinicalTrials.gov
exactly with ClinicalTrials.gov Identifier: NCT02694393
How can I change the date of this .gov database?
again : what kind of article are you talking about?
again: I'm talking about this: https://clinicaltrials.gov/show/NCT02694393
If you have some problem contact the site,please.
Pray, again , you cited an in-vitro study and the related article of the 2009-2010 , now they are testing AIR001 with patients.
Huge diiference and a great news.
Read carefully the post before to reply above all if arrogantly,please.
pray, your reply is quite unfair and unbalanced, you accuse me to pump Mast with an old "article".
Which article?
I posted a link to ClinicalTrials.gov !
Do you know that? or do you speak about biocompany without know
that there are trials to test the drugs and an official site of U.S. National Institutes of Health?
I posted also the official ID and i make a copy and past from the site.
Is my link wrong or is ClinicalTrials.gov (DOT GOV !!!) wrong?
again:
https://clinicaltrials.gov/ct2/show/NCT02694393?term=NCT02694393&rank=1
Again copy and past with the years
Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis
This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2016 by University of Pittsburgh
Sponsor:
University of Pittsburgh
Collaborators:
Mast Therapeutics, Inc.
Cystic Fibrosis Foundation Therapeutics
Information provided by (Responsible Party):
Joseph Pilewski, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT02694393
First received: January 11, 2016
Last updated: February 23, 2016
Last verified: February 2016
Estimated Enrollment: 35
Study Start Date: February 2016
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
New trial in collaboration with Mast Therapeutics AIR001.
Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis
ClinicalTrials.gov Identifier: NCT02694393
Phase 1,Phase 2
Sponsor:
University of Pittsburgh
Collaborators:
Mast Therapeutics, Inc.
Cystic Fibrosis Foundation Therapeutics
Estimated Enrollment: 35
Study Start Date: February 2016
Estimated Study Completion Date:January 2018
Estimated Primary Completion Date:January 2017 (Final data collection date for primary outcome measure)
https://clinicaltrials.gov/ct2/show/NCT02694393?term=NCT02694393&rank=1
Thank Bx, surely Mstx now has a structure very different from a bio-scam company, and the progresses in these 3 years have been remarkable,for this reason I can't understand what happened.
Surely we are in a terrible market conditions with financiers that are disinvesting and a lot of bio stock 70% discounted are an easy alternative investements ,objective facts that can in part explain an offer so low. Disappointed by the lack of explainations from the Co, I hope to hear something soon.
Also Epic could be involved in this maneuver, but Interim at 250 looked like positive, with 79 hrs overall,very low vs other trials, what could be happened?
I appreciate your points.Still long I don't want sell so low, thinking the game not finished yet.
I'd ask everyone if is not possible press Culley to resign , I think that his incautious strategy and his behaviour is making damage to the Co value.
C Icahn sold all ANX shares in 2005, yesterday he sold the remaining warrants.Not a bad news imo,only an accounting operation of EoY.
Somebody bought
AIR001 P2a results ,my guess is next Monday.
I think they will be good, as some scientific articles say.
Unlike the Vepo for AIR001 haven't seen any clear valutation about sales,could it better than scd?
AIR001 P2a results ,my guess is next Monday.
I think they will be good, as some scientific articles say.
Unlike the Vepo for AIR001 haven't seen any clear valutation about sales,could it better than scd?
Interesting.
Do you know the PT of this analyst?
TIA
the same doctor Borlaug and a very similar to Mast's AIR001 trial but invasive not via inhalation
MAST trial is registred as Aires Pharmaceuticals:
https://clinicaltrials.gov/ct2/show/NCT02262078?term=sodium+nitrite&rank=4
IMO,good results.
Martin Emanuele on youtube talks about data presented at ASH of the Mast drug vepoloxamer.
http://www.raredr.com/conferences/ash2015/vepoloxamer?utm_source=Informz&utm_medium=Rare+DR&utm_campaign=RDR_Conference_Coverage_ASH_Newsletter_3_12-7-15
ASH effect: BLUE and GBT plunge,
insted MSTX with a real drug with a general purpose in hematology begins warming up its engines.
Adam Fuerstein on twitter: "No. Sorry. I get the wishful thinking but $MSTX sickle cell drug is not the solution."
true , not the solution yet, we know, but surely the first great step forwad for SCD patients in 17 years.
a trial of Rheoth 20 years ago showed interesting results in heart attack.
Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial.
http://www.ncbi.nlm.nih.gov/pubmed/8759069
4 presentation at ASH this December about MAST Therapeutics or Purified Poloxamer 188
https://ash.confex.com/ash/2015/webprogram/Paper78865.html
https://ash.confex.com/ash/2015/webprogram/Paper84168.html
https://ash.confex.com/ash/2015/webprogram/Paper85461.html
https://ash.confex.com/ash/2015/webprogram/Paper86647.html
and another on Heart failure presented this November 30 at the 11th International Congress on Coronary Artery Disease (ICCAD 2015) in Florence-Italy
Ventricular Function, Heart? Failure
Intravenous vepoloxamer (purified poloxamer-188) for the treatment of heart failure
Hani Sabbah, Henry Ford Heart and Vascular Institute, Detroit MI, USA?
http://iccad.kenes.com/scientific-information/preliminary-list-of-invited-presentations#.Vkhtz9FdFMs
At this point Culley & C should buy shares, put their money in the company.
Increased expenses in R&D is a positive fact, a sign of dynamism, but the delay of the EPIC results is dangerous for a still-bad-reputation Co. The suspicions that few is changed since the ANX's times,is still present.
totally wrong,pray
Poloxamer188, as well known, shoved very good results in Young patients, even a small group of patients (some tens) was enough to reach the statistical significate required by FDA for approval (p value < 0.05).
Why then do they waste time in useless tests and be late with the competitors and the market?
At that point the only important test was about safety, and somethigh else less critical all done in parallel to the trial. Actually we are now discussing about the time, we are impatient for the few months left, but surely in this market and for a company with an awful past also 3 months are important for the pps.
a paper presented for the next December annual meeting of ASH
Effects of Poloxamer 188 on Red Blood Cells Membrane Properties in Sickle Cell Disease
https://ash.confex.com/ash/2015/webprogram/Paper78865.html
'Conclusion: In parallel of the phase III clinical trial studying the profit of P188 for sickle cell patients during VOCs, our results bring clarifications regarding its mode of action on RBCs. We show that P188 directly reduces blood viscosity, RBC aggregation and adhesiveness to endothelial cells, making this drug as a potential beneficial therapy in SCA. '
not normal exchanges today:volume, blocks with flat pps. Institutionals in-out? ATM?...
and down 6% as the competitor GBT ...
maybe I'm wrong on insider buying, see at the SEC site
https://www.sec.gov/cgi-bin/own-disp?action=getissuer&CIK=0001160308
Could anybody control it ,please?
thank you hboss.
This poor interest by insiders is the only concern that persist here, a real non-sense.
I found 4 abstracts about Poloxamer-188 (2 of Mast) that will be presented at the next Annual Meeting American Society of Hematology (ASH).
57th Annual Meeting next month in FL :December 5-8, 2015
It seems that there is a growing interest among hematologists about P188 effects and its specific mechanism.
https://ash.confex.com/ash/2015/webprogram/Paper78865.html
https://ash.confex.com/ash/2015/webprogram/Paper84168.html
https://ash.confex.com/ash/2015/webprogram/Paper85461.html
https://ash.confex.com/ash/2015/webprogram/Paper86647.html
It seems so straightforward ,we should ask culley, maybe as a pressing request, all together.
Other thoughts: on the contrary I saw awful Company that used insiders buying as scam,to mislead shareholders, moreover there may be some problem of insider trading:I don't think that EPIC is so blinded....
....
M.Emanuele was a doctor in the previous RheothRx trial therefore now he is a pivotal figure in Epic, he knows all the details and he can compare the trends.
About the pay, I wish that insiders were partially payed in shares, saving cash and increasing the investors trust and not least the PPS.
I read carefully. He's the Ceo and the President of Strongbridge, a recent NASDAQ IPO(SBBP)cspitalised around $200 M.
A company with a P3 trial that will finish in January and with results in June of a drug COR-3 that is a new version of Ketaconazole. COR-3 showed in P2 a very high statistical significate, then likely an easy trial.
I see a clear analogy with Mast and EPIC, above all for a commercial partnership in EU or even for a merger in SCD and in rare diseases leaving cardio/neurology field for Mast alone.
Just my opinion
Why do they invest in other ways or into a bank if they have at home the best?
likely I'll do it, but it would be better if everybody here ask Culley/insiders to support with a direct partecipation the Co.
A clear signal that they believe in that they are doing.
A move like this could easy double the market capitalisation.
.
when will insiders start buying some shares?